<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335010</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-6382</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Antibiotics (Basel, Switzerland)</Title><ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Impact of the COVID-19 Pandemic on Inpatient Antibiotic and Antifungal Drug Prescribing Volumes in Germany.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">837</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics13090837</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies found that the coronavirus disease 2019 (COVID-19) pandemic had a variable impact on the consumption of antimicrobial drugs in human medicine, with trends in several European countries differing between community and inpatient prescribing.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study analysed changes in the volumes and use density of antibacterial and antifungal drugs dispensed in acute care hospitals in Germany between 2019 and 2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Surveillance data for the four years available from 279 hospitals were expressed as the total volumes of daily doses or as use density (daily doses per 100 patient/occupied bed days) per year and analysed descriptively, using recommended hospital-adapted daily dose definitions (RDDs) and (as sensitivity analysis) WHO/ATC-defined daily dose definitions (DDD). Hospitals were stratified according to size (number of beds), university affiliation, and location (East, West, South).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant decreases in both the total number of patient days and antibacterial drug volumes in 2020 through 2022 compared with 2019. The relative changes between 2019 and 2020, 2021, and 2022 were -12.8%, -13.5%, and -13.3% for patient days, and -9.7%, -11.0%, and -10.1% for antibacterial RDDs, respectively. Broad-spectrum betalactams, notably piperacillin-tazobactam and carbapenems, increased in volume, unlike most other drug classes. The resulting antibacterial drug use density was slightly but significantly increased, with pooled means (and medians) of 43.3 (40.0) RDD/100 in 2019 compared to 44.8 (41.7), 44.5 (40.80), and 44.9 (41.7) RDD/100 in the years 2020 through 2022, respectively. Antifungal drug volumes and use density increased after 2019 and peaked in 2021 (the difference between 2019 and 2021 for total volumes was +6.4%, and that for pooled mean use density values was +22.9%, respectively). These trends were similar in the different hospital strata and comparable when DDDs instead of RDDs were used.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Similar to what has been observed in a majority of European countries, the total volume of antibacterial drug use in German acute care hospitals decreased with the pandemic, without a rebound phenomenon in 2022. In association with restricted hospital capacities and presumably more immunocompromised general medicine patients, however, inpatient prescribing of (primarily broad-spectrum) antibacterials and of antifungal drugs increased.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Winfried V</ForeName><Initials>WV</Initials><Identifier Source="ORCID">0000-0003-2550-358X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Centre, and Faculty of Medicine, Albert-Ludwigs-University, 79106 Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Akademie für Infektionsmedizin, 10789 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steib-Bauert</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Centre, and Faculty of Medicine, Albert-Ludwigs-University, 79106 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Central Pharmacy, Medius-Kliniken, 73760 Ostfildern-Ruit, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ADKA-Bundesverband Deutscher Krankenhausapotheker, 10559 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramme</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0006-6954-2360</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein Campus Lübeck, University of Lübeck, 23562 Lübeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DGI-Deutsche Gesellschaft für Infektiologie, 10789 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Först</LastName><ForeName>Gesche</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0009-6236-6597</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Centre, and Faculty of Medicine, Albert-Ludwigs-University, 79106 Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ADKA-Bundesverband Deutscher Krankenhausapotheker, 10559 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Faculty of Chemistry and Pharmacy, Albert-Ludwigs-University, 79085 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de With</LastName><ForeName>Katja</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9473-3018</Identifier><AffiliationInfo><Affiliation>DGI-Deutsche Gesellschaft für Infektiologie, 10789 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Infectious Diseases, University Hospital Carl Gustav Carus, Technical University, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DZIF TTU 08.817</GrantID><Agency>This study was in part supported by the German Center for Infection Research (DZIF) (grant TTU 08.817) and the Akademie für Infektionsmedizin.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibiotics (Basel)</MedlineTA><NlmUniqueID>101637404</NlmUniqueID><ISSNLinking>2079-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibiotic use</Keyword><Keyword MajorTopicYN="N">antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">antimicrobial stewardship</Keyword><Keyword MajorTopicYN="N">coronavirus pandemic</Keyword><Keyword MajorTopicYN="N">hospital antibiotic consumption</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335010</ArticleId><ArticleId IdType="pmc">PMC11429143</ArticleId><ArticleId IdType="doi">10.3390/antibiotics13090837</ArticleId><ArticleId IdType="pii">antibiotics13090837</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haldane V., De Foo C., Abdalla S.M., Jung A.-S., Tan M., Wu S., Chua A., Verma M., Shrestha P., Singh S., et al. Health systems resilience in managing the COVID-19 pandemic: Lessons from 28 countries. Nat. Med. 2021;27:964–980. doi: 10.1038/s41591-021-01381-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01381-y</ArticleId><ArticleId IdType="pubmed">34002090</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynihan R., Sanders S., Michaleff Z.A., Scott A.M., Clark J., To E.J., Jones M., Kitchener E., Fox M., Johansson M., et al. Impact of COVID-19 pandemic on utilisation of healthcare services: A systematic review. BMJ Open. 2021;11:e045343. doi: 10.1136/bmjopen-2020-045343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045343</ArticleId><ArticleId IdType="pmc">PMC7969768</ArticleId><ArticleId IdType="pubmed">33727273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Jin Y., Zhou L., Yang P., Qian Y., Huang X., Min M. Evaluation of health system resilience in 60 countries based on their responses to COVID-19. Front. Public Health. 2023;10:1081068. doi: 10.3389/fpubh.2022.1081068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1081068</ArticleId><ArticleId IdType="pmc">PMC9870292</ArticleId><ArticleId IdType="pubmed">36699903</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Toole R.F. The interface between COVID-19 and bacterial healthcare-associated infections. Clin. Microbiol. Infect. 2021;27:1772–1776. doi: 10.1016/j.cmi.2021.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.06.001</ArticleId><ArticleId IdType="pmc">PMC8182977</ArticleId><ArticleId IdType="pubmed">34111586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi A., Pecetta S., Bloom D.E. Global antibiotic use during the COVID-19 pandemic: Analysis of pharmaceutical sales data from 71 countries, 2020-2022. EClinicalMedicine. 2023;57:101848. doi: 10.1016/j.eclinm.2023.101848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101848</ArticleId><ArticleId IdType="pmc">PMC9900305</ArticleId><ArticleId IdType="pubmed">36776504</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford B.J., Soucy J.-P.R., Leung V., So M., Kwan A.T., Portnoff J.S., Bertagnolio S., Raybardhan S., MacFadden D.R., Daneman N. Antibiotic resistance associated with the COVID-19 pandemic: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2023;29:302–309. doi: 10.1016/j.cmi.2022.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.12.006</ArticleId><ArticleId IdType="pmc">PMC9733301</ArticleId><ArticleId IdType="pubmed">36509377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-Gabarró C., HLeung V., Vlahović-Palčevski V., Machowska A., Monnet D.L., Diaz Högberg L., ESAC-Net study group. ESAC-Net study group participants Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022. Eurosurveillance. 2023;28:2300604. doi: 10.2807/1560-7917.ES.2023.28.46.2300604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.46.2300604</ArticleId><ArticleId IdType="pmc">PMC10655206</ArticleId><ArticleId IdType="pubmed">37971660</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrobial Consumption in the EU/EEA (ESAC-Net)—Annual Epidemiological Report 2022. European Centre for Disease Prevention and Control (ECDC); Stockholm, Sweden: 2023.</Citation></Reference><Reference><Citation>Först G., de With K., Weber N., Borde J., Querbach C., Kleideiter J., Seifert C., Hagel S., Ambrosch A., Löbermann M., et al. Validation of adapted daily dose definitions for hospital antibacterial drug use evaluation: A multicentre study. J. Antimicrob. Chemother. 2017;72:2931–2937. doi: 10.1093/jac/dkx244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx244</ArticleId><ArticleId IdType="pubmed">29091214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes P.H.C., Moreira J.P.L., Thompson A.F., Machado T.L.D.S., Cerbino-Neto J., Bozza F.A. Antibiotic consumption and deviation of prescribed daily dose from the Defined Daily Dose in critical care patients: A point-prevalence study. Front. Pharmacol. 2022;13:913568. doi: 10.3389/fphar.2022.913568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.913568</ArticleId><ArticleId IdType="pmc">PMC9243753</ArticleId><ArticleId IdType="pubmed">35784694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaehn P., Holmberg C., Uhlenbrock G., Pohl A., Finkenzeller T., Pawlik M.T., Quack I., Ernstberger A., Rockmann F., Schreyer A.G. Differential trends of admissions in accident and emergency departments during the COVID-19 pandemic in Germany. BMC Emerg. Med. 2021;21:42. doi: 10.1186/s12873-021-00436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12873-021-00436-0</ArticleId><ArticleId IdType="pmc">PMC8022298</ArticleId><ArticleId IdType="pubmed">33823795</ArticleId></ArticleIdList></Reference><Reference><Citation>Schranz M., Boender T.S., Greiner T., Kocher T., Wagner B., Greiner F., Bienzeisler J., Diercke M., Grabenhenrich L., Aigner A., et al. Changes in emergency department utilisation in Germany before and during different phases of the COVID-19 pandemic, using data from a national surveillance system up to June 2021. BMC Public Health. 2023;23:799. doi: 10.1186/s12889-023-15375-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-15375-7</ArticleId><ArticleId IdType="pmc">PMC10152015</ArticleId><ArticleId IdType="pubmed">37131165</ArticleId></ArticleIdList></Reference><Reference><Citation>Oettinger V., Stachon P., Hilgendorf I., Heidenreich A., Zehender M., Westermann D., Kaier K., Mühlen C.v.Z. COVID-19 pandemic affects STEMI numbers and in-hospital mortality: Results of a nationwide analysis in Germany. Clin. Res. Cardiol. 2023;112:550–557. doi: 10.1007/s00392-022-02102-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-022-02102-2</ArticleId><ArticleId IdType="pmc">PMC9534737</ArticleId><ArticleId IdType="pubmed">36198827</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch F., Hohenstein S., Bollmann A., Meier-Hellmann A., Kuhlen R., Ritz J.P. Cholecystectomies in the COVID-19 pandemic during and after the first lockdown in Germany: An analysis of 8561 patients. J. Gastrointest. Surg. 2022;26:408–413. doi: 10.1007/s11605-021-05157-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-021-05157-0</ArticleId><ArticleId IdType="pmc">PMC8528474</ArticleId><ArticleId IdType="pubmed">34671914</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiner J., Hohenstein S., Pellissier V., König S., Winklmair C., Nachtigall I., Bollmann A., Kuhlen R. COVID-19 and severe acute respiratory infections: Monitoring trends in 421 German hospitals during the first four pandemic waves. Infect. Drug Resist. 2023;16:2775–2781. doi: 10.2147/IDR.S402313.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S402313</ArticleId><ArticleId IdType="pmc">PMC10178997</ArticleId><ArticleId IdType="pubmed">37187482</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrella A., Fortinguerra F., Pierantozzi A., Capoluongo N., Carannante N., Vecchio A.L., Bernardi F.F., Trotta F., Cangini A. Hospital antibiotic use during COVID-19 pandemic in Italy. Antibiotics. 2023;12:168. doi: 10.3390/antibiotics12010168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12010168</ArticleId><ArticleId IdType="pmc">PMC9854455</ArticleId><ArticleId IdType="pubmed">36671369</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger P.-M., Lesselingue D., Gérard A., Roghi J., Quint P., Un S., Chincholle A., Assi A., Bouchard O., Javaudin V., et al. Antibiotic consumption 2017-2022 in 30 private hospitals in France: Impact of antimicrobial stewardship tools and COVID-19 pandemic. Antibiotics. 2024;13:180. doi: 10.3390/antibiotics13020180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics13020180</ArticleId><ArticleId IdType="pmc">PMC10886305</ArticleId><ArticleId IdType="pubmed">38391566</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiss Antibiotic Resistance Report 2022–Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland. Federal Office of Public Health and Federal Food Safety and Veterinary Office; Bern, Switzerland: 2022.</Citation></Reference><Reference><Citation>Friedli O., Gasser M., Cusini A., Fulchini R., Vuichard-Gysin D., Tobler R.H., Wassilew N., Plüss-Suard C., Kronenberg A. Impact of the COVID-19 pandemic on inpatient antibiotic consumption in Switzerland. Antibiotics. 2022;11:792. doi: 10.3390/antibiotics11060792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11060792</ArticleId><ArticleId IdType="pmc">PMC9219927</ArticleId><ArticleId IdType="pubmed">35740198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzsa R., Benkő R., Hambalek H., Papfalvi E., Csupor D., Nacsa R., Csatordai M., Soós G., Hajdú E., Matuz M. Hospital antibiotic consumption before and during the COVID-19 pandemic in Hungary. Antibiotics. 2024;13:102. doi: 10.3390/antibiotics13010102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics13010102</ArticleId><ArticleId IdType="pmc">PMC10812576</ArticleId><ArticleId IdType="pubmed">38275331</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlahović-Palčevski V., Rubinić I., Payerl Pal M. Impact of the COVID-19 pandemic on hospital antimicrobial consumption in Croatia. J. Antimicrob. Chemother. 2022;77:2713–2717. doi: 10.1093/jac/dkac247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac247</ArticleId><ArticleId IdType="pubmed">35869875</ArticleId></ArticleIdList></Reference><Reference><Citation>DANMAP 2022—Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark. National Food Institute &amp; Statens Serum Institut; Lyngby/Copenhagen, Denmark: 2023.</Citation></Reference><Reference><Citation>A Report on Swedish Antibiotic Sales and Resistance in Human Medicine (SWEDRES) and Swedish Veterinary Antibiotic Resistance Monitoring (SVARM) 2022. Public Health Agency of Sweden &amp; National Veterinary Institute; Solna/Uppsala, Sweden: 2023.</Citation></Reference><Reference><Citation>NethMap 2022—Consumption of Antimicrobial Agents and Antimicrobial Resistance among Medically Important Bacteria in the Netherlands in 2021. SWAB—the Dutch Foundation of the Working Party on Antibiotic Policy &amp; RIVM—The National Institute for Public Health and the Environment of the Netherlands; Bilthoven, The Netherlands: 2022.</Citation></Reference><Reference><Citation>Grau S., Hernández S., Echeverría-Esnal D., Almendral A., Ferrer R., Limón E., Horcajada J.P., on behalf of the Catalan Infection Control Antimicrobial Stewardship Program (VINCat-PROA) Antimicrobial consumption among 66 acute care hospitals in Catalonia: Impact of the COVID-19 pandemic. Antibiotics. 2021;10:943. doi: 10.3390/antibiotics10080943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10080943</ArticleId><ArticleId IdType="pmc">PMC8388964</ArticleId><ArticleId IdType="pubmed">34438993</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldeyab M.A., Crowe W., Karasneh R.A., Patterson L., Sartaj M., Ewing J., Lattyak W.J., Al-Azzam S., Araydah M., Elhajji F.D., et al. The impact of the COVID-19 pandemic on antibiotic consumption and prevalence of pathogens in primary and secondary healthcare settings in Northern Ireland. Br. J. Clin. Pharmacol. 2023;89:2851–2866. doi: 10.1111/bcp.15778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15778</ArticleId><ArticleId IdType="pubmed">37160725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein R.R., Rabie A.S.I., Bin Shaman M., Shaaban A.H., Fahmy A.M., Sofy M.R., A Lattyak E., Abuelhana A., A Naguib I., Ashour A.M., et al. Antibiotic consumption in hospitals during COVID-19 pandemic: A comparative study. J. Infect. Dev. Ctries. 2022;16:1679–1686. doi: 10.3855/jidc.17148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.17148</ArticleId><ArticleId IdType="pubmed">36449638</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Leary E.N., Neuhauser M.M., Srinivasan A., Dubendris H., Webb A.K., Soe M.M., Hicks L.A., Wu H., Kabbani S., Edwards J.R. Impact of the COVID-19 pandemic on inpatient antibiotic use in the United States, January 2019 through July 2022. Clin. Infect. Dis. 2024;78:24–26. doi: 10.1093/cid/ciad453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad453</ArticleId><ArticleId IdType="pubmed">37536269</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel T.S., McGovern O.L., Mahon G., Osuka H., Boszczowski I., Munita J.M., Garzon M.I., Salomao M.C., Marssola G., Tavares B.M., et al. Trends in inpatient antibiotic use among adults hospitalized during the Coronavirus Disease 2019 pandemic in Argentina, Brazil, and Chile, 2018-2021. Clin. Infect. Dis. 2023;77((Suppl. S1)):S4–S11. doi: 10.1093/cid/ciad261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad261</ArticleId><ArticleId IdType="pubmed">37406043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B., Hwang H., Chae J., Kim Y.S., Kim D.S. Analysis of changes in antibiotic use patterns in Korean hospitals during the COVID-19 pandemic. Antibiotics. 2023;12:198. doi: 10.3390/antibiotics12020198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12020198</ArticleId><ArticleId IdType="pmc">PMC9952207</ArticleId><ArticleId IdType="pubmed">36830109</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Fairfield C.J., Drake T.M., Seaton R.A., Sigfrid L., Harrison E.M., Docherty A.B., I de Silva T., Egan C., Pius R., et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: A multicentre, prospective cohort study. Lancet Microbe. 2021;2:e354–e365. doi: 10.1016/S2666-5247(21)00090-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00090-2</ArticleId><ArticleId IdType="pmc">PMC8172149</ArticleId><ArticleId IdType="pubmed">34100002</ArticleId></ArticleIdList></Reference><Reference><Citation>Allel K., Peters A., Conejeros J., Martínez J.R.W., Spencer-Sandino M., Riquelme-Neira R., Rivas L., Rojas P., Chea C.O., García P., et al. Antibiotic Consumption During the Coronavirus Disease 2019 Pandemic and Emergence of Carbapenemase-Producing Klebsiella pneumoniae Lineages Among Inpatients in a Chilean Hospital: A Time-Series Study and Phylogenomic Analysis. Clin. Infect. Dis. 2023;77((Suppl. S1)):S20–S28. doi: 10.1093/cid/ciad151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad151</ArticleId><ArticleId IdType="pmc">PMC10321701</ArticleId><ArticleId IdType="pubmed">37406053</ArticleId></ArticleIdList></Reference><Reference><Citation>Abubakar U., Al-Anazi M., Alanazi Z., Rodríguez-Baño J. Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review. J. Infect. Public Health. 2023;16:320–331. doi: 10.1016/j.jiph.2022.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.12.022</ArticleId><ArticleId IdType="pmc">PMC9804969</ArticleId><ArticleId IdType="pubmed">36657243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sili U., Tekin A., Bilgin H., Khan S.A., Domecq J.P., Vadgaonkar G., Segu S.S., Rijhwani P., Raju U., Surapaneni K.M., et al. Early empiric antibiotic use in COVID-19 patients: Results from the international VIRUS registry. Int. J. Infect. Dis. 2024;140:39–48. doi: 10.1016/j.ijid.2023.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.12.006</ArticleId><ArticleId IdType="pmc">PMC10939992</ArticleId><ArticleId IdType="pubmed">38128643</ArticleId></ArticleIdList></Reference><Reference><Citation>Durà-Miralles X., Abelenda-Alonso G., Bergas A., Laporte-Amargós J., Sastre-Escolà E., Padullés A., Carratalà J., Gudiol C. An Ocean between the Waves: Trends in Antimicrobial Consumption in Hospitalized Patients with COVID-19. Antibiotics. 2024;13:55. doi: 10.3390/antibiotics13010055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics13010055</ArticleId><ArticleId IdType="pmc">PMC10812529</ArticleId><ArticleId IdType="pubmed">38247614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenigl M., Seidel D., Sprute R., Cunha C., Oliverio M., Goldman G.H., Ibrahim A.S., Carvalho A. COVID-19-associated fungal infections. Nat. Microbiol. 2022;7:1127–1140. doi: 10.1038/s41564-022-01172-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01172-2</ArticleId><ArticleId IdType="pmc">PMC9362108</ArticleId><ArticleId IdType="pubmed">35918423</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretagne S., Sitbon K., Botterel F., Dellière S., Letscher-Bru V., Chouaki T., Bellanger A.-P., Bonnal C., Fekkar A., Persat F., et al. COVID-19-associated aspergillosis, fungemia, and pneumocystosis in the intensive care unit: A retrospective multicenter observational cohort during the first French pandemic wave. Microbiol. Spectr. 2021;9:e0113821. doi: 10.1128/Spectrum.01138-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01138-21</ArticleId><ArticleId IdType="pmc">PMC8528108</ArticleId><ArticleId IdType="pubmed">34668768</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz M., Korem M., Ayalon O., Wiener-Well Y., Shachor-Meyouhas Y., Cohen R., Bishara J., Atamna A., Brosh-Nissimov T., Maaravi N., et al. Invasive fungal diseases in hospitalized patients with COVID-19 in Israel: A multicenter cohort study. J. Fungi. 2022;8:721. doi: 10.3390/jof8070721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof8070721</ArticleId><ArticleId IdType="pmc">PMC9317957</ArticleId><ArticleId IdType="pubmed">35887476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangneux J.-P., Dannaoui E., Fekkar A., Luyt C.-E., Botterel F., De Prost N., Tadié J.-M., Reizine F., Houzé S., Timsit J.-F., et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study. Lancet Respir. Med. 2022;10:180–190. doi: 10.1016/S2213-2600(21)00442-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00442-2</ArticleId><ArticleId IdType="pmc">PMC8626095</ArticleId><ArticleId IdType="pubmed">34843666</ArticleId></ArticleIdList></Reference><Reference><Citation>Koulenti D., Karvouniaris M., Paramythiotou E., Koliakos N., Markou N., Paranos P., Meletiadis J., Blot S. Severe Candida infections in critically ill patients with COVID-19. J. Intensive Med. 2023;3:291–297. doi: 10.1016/j.jointm.2023.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jointm.2023.07.005</ArticleId><ArticleId IdType="pmc">PMC10658040</ArticleId><ArticleId IdType="pubmed">38028641</ArticleId></ArticleIdList></Reference><Reference><Citation>Prigitano A., Blasi E., Calabrò M., Cavanna C., Cornetta M., Farina C., Grancini A., Innocenti P., Cascio G.L., Nicola L., et al. Yeast bloodstream infections in the COVID-19 patient: A multicenter Italian study (FiCoV Study) J. Fungi. 2023;9:277. doi: 10.3390/jof9020277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof9020277</ArticleId><ArticleId IdType="pmc">PMC9962415</ArticleId><ArticleId IdType="pubmed">36836391</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuniga-Moya J.C., Papadopoulos B., Mansoor A.E., Mazi P.B., Rauseo A.M., Spec A. Incidence and mortality of COVID-19-associated invasive fungal infections among critically ill intubated patients: A multicenter retrospective cohort analysis. Open Forum Infect. Dis. 2024;11:ofae108. doi: 10.1093/ofid/ofae108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae108</ArticleId><ArticleId IdType="pmc">PMC10986750</ArticleId><ArticleId IdType="pubmed">38567199</ArticleId></ArticleIdList></Reference><Reference><Citation>Leistner R., Schroeter L., Adam T., Poddubnyy D., Stegemann M., Siegmund B., Maechler F., Geffers C., Schwab F., Gastmeier P., et al. Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. Crit. Care. 2022;26:30. doi: 10.1186/s13054-022-03902-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03902-8</ArticleId><ArticleId IdType="pmc">PMC8796178</ArticleId><ArticleId IdType="pubmed">35090528</ArticleId></ArticleIdList></Reference><Reference><Citation>Prattes J., Wauters J., Giacobbe D.R., Salmanton-García J., Maertens J., Bourgeois M., Reynders M., Rutsaert L., Van Regenmortel N., Lormans P., et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. 2022;28:580–587. doi: 10.1016/j.cmi.2021.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.08.014</ArticleId><ArticleId IdType="pmc">PMC8387556</ArticleId><ArticleId IdType="pubmed">34454093</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hesselle M.L., Borgmann S., Rieg S., Vehreshild J.J., Spinner C.D., Koll C.E.M., Hower M., Stecher M., Ebert D., Hanses F., et al. Invasiveness of ventilation therapy is associated to prevalence of secondary bacterial and fungal infections in critically ill COVID-19 patients. J. Clin. Med. 2022;11:5239. doi: 10.3390/jcm11175239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175239</ArticleId><ArticleId IdType="pmc">PMC9457079</ArticleId><ArticleId IdType="pubmed">36079168</ArticleId></ArticleIdList></Reference><Reference><Citation>Timsit J.F. After SARS-CoV-2 pandemics: New insights into ICU-acquired pneumonia. J. Clin. Med. 2023;12:2160. doi: 10.3390/jcm12062160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12062160</ArticleId><ArticleId IdType="pmc">PMC10059993</ArticleId><ArticleId IdType="pubmed">36983162</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook P., Logan C., Mazzella A., Wake R.M., Cusinato M., Yau T., Ong Y.-E., Planche T., Basarab M., Bicanic T. The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: A retrospective cohort study. BMC Infect. Dis. 2023;23:808. doi: 10.1186/s12879-023-08697-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08697-9</ArticleId><ArticleId IdType="pmc">PMC10656831</ArticleId><ArticleId IdType="pubmed">37978457</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad P.J., Poles J., Zacharioudakis I.M., Dubrovskaya Y., Delpachitra D., Iturrate E., Muñoz-Gómez S. Coinfections and antimicrobial use in patients hospitalized with coronavirus disease 2019 (COVID-19) across a single healthcare system in New York City: A retrospective cohort study. Antimicrob. Steward. Healthc. Epidemiol. 2022;2:e78. doi: 10.1017/ash.2022.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.51</ArticleId><ArticleId IdType="pmc">PMC9726479</ArticleId><ArticleId IdType="pubmed">36483377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienvenu A.-L., Bestion A., Pradat P., Richard J.-C., Argaud L., Guichon C., Roux S., Piriou V., Paillet C., Leboucher G., et al. Impact of COVID-19 pandemic on antifungal consumption: A multicenter retrospective analysis. Crit. Care. 2022;26:384. doi: 10.1186/s13054-022-04270-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04270-z</ArticleId><ArticleId IdType="pmc">PMC9745268</ArticleId><ArticleId IdType="pubmed">36514110</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Bond S.E., Lee-Milner J., Conway B.R., Lattyak W.J., Aldeyab M.A. Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: Intervention time series analysis. JAC Antimicrob. Resist. 2024;6:dlae013. doi: 10.1093/jacamr/dlae013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlae013</ArticleId><ArticleId IdType="pmc">PMC10848649</ArticleId><ArticleId IdType="pubmed">38328263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>